top of page
Bad Blood


technology & future

Bad Blood

John Carreyrou

What is the book about?

The book Bad Blood (2018) is about a Silicon Valley startup, Theranos, that promised to revolutionize the medical industry by creating a device that could perform multiple blood tests with just a few drops of blood. However, behind the scenes, the company was riddled with lies, deceit, and fraud, leading to its downfall and the downfall of its founder, Elizabeth Holmes.

Who should read the book?

This book is a perfect read for individuals who are interested in the world of startups, entrepreneurship and technology, and who appreciate investigative journalism that uncovers the truth behind complex business scandals. They are curious, critical thinkers who value integrity and transparency in the corporate world.

About the Author:

John Carreyrou is a Pulitzer Prize-winning investigative journalist. He worked at The Wall Street Journal for over 20 years, where he broke the story of the Theranos scandal. Carreyrou's tenacious reporting revealed the fraudulent practices of the healthcare company and led to its downfall. He is known for his in-depth investigative work and dedication to uncovering the truth.

Book Summary

Three Key Ideas - find more in our App!

Get ready to dive into the thrilling world of Silicon Valley and the rise and fall of a once-promising startup. In "Bad Blood," John Carreyrou takes us on a heart-pounding journey through the story of Theranos, a company that promised to revolutionize the medical industry with a revolutionary blood testing device. However, what began as a game-changing idea quickly spiraled into a web of lies, deception, and fraud. As you read this book, you'll uncover the shocking truth behind the scandal that rocked the tech industry and learn about the key players involved in the downfall of one of the most infamous startups in history. You'll also gain insights into the complex personalities and motivations that drove the individuals behind the company's rise and eventual collapse. So buckle up and get ready for a wild ride, as "Bad Blood" takes you on a gripping journey through the dark side of entrepreneurship and the high stakes world of Silicon Valley.

Elizabeth Holmes' vision for Theranos: revolutionize healthcare with a drop of blood

The concept of revolutionizing healthcare with a drop of blood was the driving force behind Elizabeth Holmes' vision for Theranos. She aimed to create a technology that could take multiple tests from a single drop of blood, instead of using the traditional method of drawing vials of blood from patients. Holmes believed that this would make healthcare more accessible, affordable, and convenient for people.

To achieve this goal, Holmes founded Theranos in 2003, and soon the company gained attention and funding from high-profile investors due to its innovative technology. However, as John Carreyrou highlights in Bad Blood, the reality was very different from the image portrayed by Holmes and the company.

Behind the scenes, there were major problems with the technology and the accuracy of the results. The machines often failed quality control tests, and the results were not always reliable. Despite this, Holmes continued to promote the technology to investors, partners, and the public, and even went as far as making false claims about the company's progress and partnerships.

Holmes' vision for Theranos was doomed to fail due to the lack of scientific evidence, the secrecy within the company, and the fear-based culture that discouraged employees from speaking out about the problems. However, at the same time, her vision was inspiring and attracted many people to join Theranos and invest in the company.

Overall, Elizabeth Holmes' vision for Theranos was a noble one, but the execution was flawed, and the company ultimately failed. Her story serves as a cautionary tale about the dangers of blind ambition and the importance of transparency and scientific evidence in revolutionary ideas.

Early success and highprofile partnerships masked major problems

The key idea discussed here is how early success and impressive partnerships can hide significant issues within a company. The author showcases the case of Elizabeth Holmes, the founder of Theranos, who convinced investors and partners that her company was revolutionizing healthcare with a drop of blood. However, the company's success was based on false promises and lies.

Holmes aimed to create a device that could carry out a wide range of medical tests using a small amount of blood, thereby eliminating the need for invasive procedures and making healthcare more accessible. Even though this technology was not yet feasible, Holmes secured millions of dollars in funding and partnerships with major companies.

As the company expanded, it became clear that the technology was not functioning as promised, and the test results were inaccurate. Nonetheless, the company continued to tout its success and growth, despite being founded on false promises and lies.

The author shares numerous anecdotes and examples to illustrate this key idea. For example, he explains how Holmes and her team manipulated test results to make them seem more accurate than they actually were. Additionally, he describes how the company managed to conceal its issues from investors and partners using an intensely secretive culture and fear-based tactics.

Despite the growing evidence that Theranos was not what it claimed to be, many investors and partners continued to support the company. Only through the efforts of whistleblowers and journalists did the truth finally come to light.

In conclusion, this key idea highlights how early success and impressive partnerships can hide significant problems within a company. Through the case of Theranos, the author demonstrates how Elizabeth Holmes convinced investors and partners that her company was transforming healthcare, even though it was built on a foundation of falsehoods and empty promises. The author's use of anecdotes and examples shows how the company was able to keep its issues hidden from those who were investing in and partnering with it.

bottom of page